ATyr Pharma presents research on new fibrosis treatment ATYR0101 at upcoming Keystone Symposia.

ATyr Pharma, a biotech company, will present two posters on its candidate ATYR0101 at the Keystone Symposia on Fibrosis from December 8-11, 2024, in Canada. The posters will discuss the drug's anti-fibrotic effects in lung and kidney models and its interaction with proteins that may help treat fibrosis and inflammation. ATYR0101 is part of ATyr's efforts to develop new therapies based on tRNA synthetase biology.

November 15, 2024
3 Articles

Further Reading